YTHDF2 can also promote immune evasion and angiogenesis in liver cancer by recognizing the m6A modification site in the 5’UTR of ETS variant transcription factor 5 mRNA and recruiting the eukaryotic translation initiation factor 3 subunit B to facilitate its translation [47]. Here, EIF3B is linked to liver cancer.